Mankind Pharma

Mankind Pharma Ltd. reported a net profit of Rs. 414 crore for the third quarter, reflecting a 9.5% year-on-year increase, driven by stable domestic sales and operational efficiency. Revenue growth was supported by consistent performance across the company’s therapeutic segments, including cardiovascular, dermatology and OTC products. Analysts said the results underscore Mankind Pharma’s resilience amid competitive pressures in India’s pharmaceutical sector, aided by strong distribution reach and cost discipline.

Mankind Pharma has announced its decision to form a committee aimed at evaluating various options for integrating Bharat Serums and Vaccines (BSV) into its operations. This move follows the successful completion of a Rs. 13,768 crore acquisition of BSV in October 2024. The company plans to explore different structural alternatives for the integration process, with a concrete plan expected to be presented to the board in the coming months. The proposal will undergo consultation with financial, legal, and tax advisors and will require approval from shareholders, creditors, and regulators.